Effect of Roux-en-Y Gastric Bypass vs Sleeve Gastrectomy on Glucose and Gut Hormones: A Prospective Randomised Trial

Journal of Gastrointestinal Surgery

Volumn 16, Issue 6, 2012, Pages 1116-1122

  Ramón, José Manuel ^a   Salvans, Silvia ^a   Crous, Xenia ^a   Puig, Sonia ^a   Goday, Albert ^a,b   Benaiges, David ^a,b   Trillo, Lourdes ^a   Pera, Manuel ^a   Grande, Luis ^a  

^a HOSPITAL DEL MAR   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

Glucose metabolism; Gut hormones; Roux en Y gastric bypass; Sleeve gastrectomy

Indexed keywords

BIOLOGICAL MARKER; GASTROINTESTINAL HORMONE;

ADOLESCENT; ADULT; ARTICLE; BLOOD; BODY MASS; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; GASTRECTOMY; GLUCOSE BLOOD LEVEL; HUMAN; LAPAROSCOPY; METABOLISM; METHODOLOGY; MIDDLE AGED; OBESITY; POSTOPERATIVE PERIOD; PROSPECTIVE STUDY; RADIOIMMUNOASSAY; RANDOMIZED CONTROLLED TRIAL; STOMACH BYPASS; TIME; TREATMENT OUTCOME;

ADOLESCENT; ADULT; BIOLOGICAL MARKERS; BLOOD GLUCOSE; BODY MASS INDEX; FEMALE; FOLLOW-UP STUDIES; GASTRECTOMY; GASTRIC BYPASS; GASTROINTESTINAL HORMONES; HUMANS; LAPAROSCOPY; MIDDLE AGED; OBESITY; POSTOPERATIVE PERIOD; PROSPECTIVE STUDIES; RADIOIMMUNOASSAY; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84861719742     PISSN: 1091255X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11605-012-1855-0     Document Type: Article

References (44)

1. Sturm R. Increases in morbid obesity in the USA: 2000-2005. Public Health. 2007; 121: 492-6.
2. Haslam DW, James WP. Obesity. Lancet. 2005; 366: 1197-209.
3. Sjostrom CD, Lissner L, Wedel H, Sjostrom L. Reduction in incidence of diabetes, hypertension and lipid disturbances after intentional weight loss induced by bariatric surgery: the SOS Intervention Study. Obes Res. 1999; 7: 477-84.
4. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002; 346: 393-403.
5. Colquitt JL, Picot J, Loveman E, et al. Surgery for obesity. Cochrane Database Syst Rev. 2009: CD003641.
6. Sjostrom L, Lindroos AK, Peltonen M, et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med. 2004; 351: 2683-93.
7. Buchwald H, Avidor Y, Braunwald E, et al. Bariatric surgery: a systematic review and meta-analysis. JAMA. 2004; 292: 1724-37.
8. Karmali S, Schauer P, Birch D, et al. Laparoscopic sleeve gastrectomy: an innovative new tool in the battle against the obesity epidemic in Canada. Can J Surg. 2010; 53: 126-32.
9. Baltasar A, Serra C, Perez N, et al. Laparoscopic sleeve gastrectomy: a multi-purpose bariatric operation. Obes Surg. 2005; 15: 1124-8.
10. Abu-Jaish W, Rosenthal RJ. Sleeve gastrectomy: a new surgical approach for morbid obesity. Expert Rev Gastroenterol Hepatol. 2010; 4: 101-19.
11. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985; 28: 412-9.
12. Goday A, Gabriel R, Ascaso JF, et al. [Cardiovascular risk in subjects with high probability of metabolic syndrome and insulin resistance. DESIRE study]. Rev Clin Esp. 2008; 208: 377-85.
13. le Roux CW, Aylwin SJ, Batterham RL, et al. Gut hormone profiles following bariatric surgery favor an anorectic state, facilitate weight loss, and improve metabolic parameters. Ann Surg. 2006; 243: 108-14.
14. Schauer PR, Burguera B, Ikramuddin S, et al. Effect of laparoscopic Roux-en Y gastric bypass on type 2 diabetes mellitus. Ann Surg. 2003; 238: 467-84.
15. Maggard MA, Shugarman LR, Suttorp M, et al. Meta-analysis: surgical treatment of obesity. Ann Intern Med. 2005; 142: 547-59.
16. Rubino F, Schauer PR, Kaplan LM, et al. Metabolic surgery to treat type 2 diabetes: clinical outcomes and mechanisms of action. Annu Rev Med. 2010; 61: 393-411.
17. Angrisani L, Lorenzo M, Borrelli V. Laparoscopic adjustable gastric banding versus Roux-en-Y gastric bypass: 5-year results of a prospective randomized trial. Surg Obes Relat Dis. 2007; 3: 127-32.
18. Biertho L, Steffen R, Ricklin T, et al. Laparoscopic gastric bypass versus laparoscopic adjustable gastric banding: a comparative study of 1, 200 cases. J Am Coll Surg. 2003; 197: 536-44.
19. Rubino F, Gagner M, Gentileschi P, et al. The early effect of the Roux-en-Y gastric bypass on hormones involved in body weight regulation and glucose metabolism. Ann Surg. 2004; 240: 236-42.
20. Rubino F, Forgione A, Cummings DE, et al. The mechanism of diabetes control after gastrointestinal bypass surgery reveals a role of the proximal small intestine in the pathophysiology of type 2 diabetes. Ann Surg. 2006; 244: 741-9.
21. Benaiges D, Goday A, Ramon J. M., Hernandez E, et al. Laparoscopic Sleeve Gastrectomy and laparoscopic gastric bypass are equally effective for reduction of cardiovascular risk in severely obese patients at 1 year follow Up. Surg Obes Relat Dis. 2011.
22. Lakdawala MA, Bhasker A, Mulchandani D, et al. Comparison between the results of laparoscopic sleeve gastrectomy and laparoscopic Roux-en-Y gastric bypass in the Indian population: a retrospective 1 year study. Obes Surg. 2010; 20: 1-6.
23. Vidal J, Ibarzabal A, Nicolau J, et al. Short-term effects of sleeve gastrectomy on type 2 diabetes mellitus in severely obese subjects. Obes Surg. 2007; 17: 1069-74.
24. Ponce J, Haynes B, Paynter S, et al. Effect of Lap-Band-induced weight loss on type 2 diabetes mellitus and hypertension. Obes Surg. 2004; 14: 1335-42.
25. Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev. 2007; 87: 1409-39.
26. Meier JJ, Gallwitz B, Salmen S, et al. Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes. J Clin Endocrinol Metab. 2003; 88: 2719-25.
27. Braghetto I, Davanzo C, Korn O, et al. Scintigraphic evaluation of gastric emptying in obese patients submitted to sleeve gastrectomy compared to normal subjects. Obes Surg. 2009; 19: 1515-21.
28. Vincent RP, le Roux CW. The satiety hormone peptide YY as a regulator of appetite. J Clin Pathol. 2008; 6: 548-52.
29. Karamanakos SN, Vagenas K, Kalfarentzos F, et al. Weight loss, appetite suppression, and changes in fasting and postprandial ghrelin and peptide-YY levels after Roux-en-Y gastric bypass and sleeve gastrectomy: a prospective, double blind study. Ann Surg. 2008; 247: 401-7.
30. Pournaras DJ, Osborne A, Hawkins SC, et al. The gut hormone response following Roux-en-Y gastric bypass: cross-sectional and prospective study. Obes Surg. 2010; 20: 56-60.
31. Peterli R, Wolnerhanssen B, Peters T, et al. Improvement in glucose metabolism after bariatric surgery: comparison of laparoscopic Roux-en-Y gastric bypass and laparoscopic sleeve gastrectomy: a prospective randomized trial. Ann Surg. 2009; 250: 234-41.
32. Kojima M, Hosoda H, Date Y, et al. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature. 1999; 402: 656-60.
33. Tschop M, Smiley DL, Heiman ML. Ghrelin induces adiposity in rodents. Nature. 2000; 407: 908-13.
34. Tschop M, Weyer C, Tataranni PA, et al. Circulating ghrelin levels are decreased in human obesity. Diabetes. 2001; 50: 707-9.
35. Cummings DE, Weigle DS, Frayo RS, et al. Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. N Engl J Med. 2002; 346: 1623-30.
36. Yada T, Dezaki K, Sone H, et al. Ghrelin regulates insulin release and glycemia: physiological role and therapeutic potential. Curr Diabetes Rev. 2008; 4: 18-23.
37. Kelesidis T, Kelesidis I, Chou S, et al. Narrative review: the role of leptin in human physiology: emerging clinical applications. Ann Intern Med. 2010; 152: 93-100.
38. Sorensen TI, Echwald S, Holm JC. Leptin in obesity. BMJ. 1996; 313: 953-4.
39. Liou JM, Lin JT, Lee WJ, et al. The serial changes of ghrelin and leptin levels and their relations to weight loss after laparoscopic minigastric bypass surgery. Obes Surg. 2008; 18: 84-9.
40. Kotidis EV, Koliakos G, Papavramidis TS. The effect of biliopancreatic diversion with pylorus-preserving sleeve gastrectomy and duodenal switch on fasting serum ghrelin, leptin and adiponectin levels: is there a hormonal contribution to the weight-reducing effect of this procedure? Obes Surg. 2006; 16: 554-9.
41. Geloneze B, Tambascia MA, Pareja JC, et al. Serum leptin levels after bariatric surgery across a range of glucose tolerance from normal to diabetes. Obes Surg. 2001; 11: 693-8.
42. Hickey MS, Pories WJ, MacDonald KG, Jr., et al. A new paradigm for type 2 diabetes mellitus: could it be a disease of the foregut? Ann Surg. 1998; 227: 637-43.
43. Jayasena CN, Bloom SR. Role of gut hormones in obesity. Endocrinol Metab Clin North Am. 2008; 37: 769-87.
44. Vidal J, Ibarzabal A, Romero F, et al. Type 2 diabetes mellitus and the metabolic syndrome following sleeve gastrectomy in severely obese subjects. Obes Surg. 2008; 18: 1077-82.